1428073-16-8

Upstream product

• 81-07-2 saccharin 
• 1612763-46-8 tert-butyl 4-[(1,1,3-trioxo-2,3-dihydro-1λ,2-benzothiazol-2-yl)methyl]benzoate 
• 694473-93-3 4-[(1,1,3-Trioxo-2,3-dihydro-1λ⁶,2-benzothiazol-2-yl)methyl]benzoic acid 
• 1612763-47-9 4-[(1,1,3-Trioxo-2,3-dihydro-1λ⁶,2-benzothiazol-2-yl)methyl]benzoyl chloride 
• 108052-76-2 4-(bromomethyl)benzoic acid 1,1-dimethylethyl ester 

Downstream Products

• 1612763-48-0 tert-butyl N-[(tert-butoxy)carbonyl]-N-{4-[(1,1,3-trioxo-2,3-dihydro-1λ⁶,2-benzothiazol-2-yl)methyl]benzoyl}carbamate 

Relevant academic research and scientific papers

Saccharin derivatives as inhibitors of interferon-mediated inflammation

A series of novel, saccharin-based antagonists have been identified for the interferon signaling pathway. Through in vitro high-throughput screening with the Colorado Center for Drug Discovery (C2D2) Pilot Library, we identified hit compound 1, which was the basis for extensive structure-activity relationship studies. Our efforts produced a lead anti-inflammatory compound, tert-butyl N-(furan-2-ylmethyl)-N-{4-[(1,1,3-trioxo-2,3-dihydro-1λ6,2- benzothiazol-2-yl)methyl]benzoyl}carbamate CU-CPD103 (103), as a potent inhibitor using an established nitric oxide (NO) signaling assay. With further studies of its inhibitory mechanisms, we demonstrated that 103 carries out this inhibition through the JAK/STAT1 pathway, providing a drug-like small molecule inflammation suppressant for possible therapeutic uses.